参一胶囊联合GP方案治疗晚期非小细胞肺癌临床观察

doi:10.3971/j.issn.1000-8578.2012.09.017

参一胶囊联合GP方案治疗晚期非小细胞肺癌临床观察

Clinical Study of GP Regimen Plus Gensing Rg3 in Treatment of Advanced Non-small Cell Lung Cancer

摘要

摘要: 目的观察参一胶囊联合GP方案治疗晚期非小细胞肺癌（NSCLC）的临床疗效和患者的耐受性。方法77例晚期非小细胞肺癌患者随机分组，治疗组39例采用参一胶囊加GP方案;对照组38例，仅采用GP方案。结果治疗组近期有效率48.7%，临床获益率82.1%；对照组有效率36.8%，临床获益率63.2%，有效率两组比较差异无统计学意义（P＞0.05），临床获益率两组比较差异有统计学意义(P<0.05)。主要不良反应为骨髓抑制和恶心呕吐，治疗组Ⅲ/Ⅳ度反应明显低于对照组，两组比较差异有统计学意义。结论参一胶囊联合GP方案对晚期非小细胞肺癌具有增加疗效，减轻不良反应，提高患者耐受性的作用，值得临床推广应用。

Abstract: Objective To study the clinical effect and toleration of Rg3 combination with chemotherapy regimen—GP in patients with advanced non-small cell lung cancer (NSCLC). Methods Seventy-seven patients were divided into two groups randomly.Thirty-nine patients as treatment group,treated by Rg3 plus GP regimen,and thirty-eight patients as the control group,only treated by GP regimen. Results The response rate was 48.7% in treatment group and 36.8% in control,The clinical benefit rate (disease control rate) was 82.1% and 63.2% respectively (P<0.05). Conclusion Rg3 combined with GP regimen could increase the therapeutic effects and decrease the side effects of chemotherapy in the patients with advanced non-small cell lung cancer.

HTML全文

参考文献(11)

施引文献

资源附件(0)